New Orleans-based biotech company Obatala Sciences has just closed a $3 million Series A funding round co-led by être Venture Capital and Ochsner Lafayette General Healthcare Innovation Fund II.
Obatala Sciences is known for developing products and services to aid in the research and treatment for diseases such as diabetes, obesity, and some cancers. According to the company, “the funding will be used to further the commercialization of its first-of-kind research-enabling products and platform for drug discovery and development.”
Additional investors include Benson Capital Partners, Elevate Capital Fund, and the Hackett-Robertson-Tobe Group.
In June 2021, Harvard allowed Obatala Sciences to license its technology to further advance its work down in New Orleans. The company was later included on the November 2021 list of must-watch startups in New Orleans compiled by entrepreneur support organization The Idea Village. Obatala Sciences was also named a top New Orleans startup of the year by Startup Hustle back in March 2022.
Visit obatalasciences.com to learn more.